Hengrui PD-1 nasopharyngeal carcinoma indication is officially approved

April 29, NMPA official website shows, Ka Ruili natalizumab new indications approved on the market, use for previously treated with second-line chemotherapy, disease progression and after more or intolerable advanced nasopharyngeal carcinoma patients
.

At the 2020 ESMO conference, Hengrui announced the clinical results of the national multi-center, single-arm clinical trial CAPTAIN study
.

The trial included 156 patients with recurrent/metastatic nasopharyngeal carcinoma who had failed ≥2 lines of treatment

The results of the study with a median follow-up of 9.

2 months showed that the ORR reached 28.
2%, the 12-month DoR rate was 58.
5%, the median PFS was 3.

Currently in China, Hengrui's main competitor for nasopharyngeal cancer indications is Junshi
.

Among the domestically approved PD-1s, only Hengrui and Junshi have reported on the market for nasopharyngeal cancer indications, including third-line and first-line treatments for nasopharyngeal cancer
.
Junshi is slightly faster than Hengrui, and was approved for third-line therapy on February 10 this year
.
Hengrui’s PD-1 indications are reported in China.
The incidence and mortality of nasopharyngeal cancer are significantly higher than the world average.
50% of the world’s nasopharyngeal cancers occur in China
.
Radiotherapy is the main method for the treatment of early-stage nasopharyngeal carcinoma, but about 20-37% of patients will have local recurrence or distant metastasis
.
The treatment options for recurrent or metastatic nasopharyngeal carcinoma are very limited and the prognosis is poor
.